

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202241005079 A

(19) INDIA

(22) Date of filing of Application :31/01/2022

(43) Publication Date : 23/12/2022

(54) Title of the invention : A synergistic composition and its intranasal pharmaceutical formulation for treatment and/or management of multiple sclerosis

(51) International classification :A61K0009000000, A61K0031704000, A61K0031137000, C12N0015113000, A61K0031445000

(86) International Application No Filing Date :PCT// / :01/01/1900

(87) International Publication No : NA

(61) Patent of Addition to Application Number Filing Date :NA :NA

(62) Divisional to Application Number Filing Date :NA :NA

(71)Name of Applicant :

1)JSS Academy of Higher Education and Research

Address of Applicant :Bannimantap Road, Sri Shivarathreeshwara Nagara, Bannimantap A Layout, Bannimantap, Mysuru – 570 015, Karnataka, India. -----

Name of Applicant : NA

Address of Applicant : NA

(72)Name of Inventor :

1)Vishal Kumar Gupta

Address of Applicant :Department of Pharmaceutics, JSS College of Pharmacy, Bannimantap Road, Sri Shivarathreeshwara Nagara, Bannimantap A Layout, Bannimantap, Mysuru – 570 015, Karnataka, India. -----

2)Koduru Trideva Sastri

Address of Applicant :Department of Pharmaceutics, JSS College of Pharmacy, Bannimantap Road, Sri Shivarathreeshwara Nagara, Bannimantap A Layout, Bannimantap, Mysuru – 570 015, Karnataka, India. -----

(57) Abstract :

ABSTRACT Title: A synergistic composition and its intranasal pharmaceutical formulation for treatment and/or management of multiple sclerosis Multiple sclerosis (MS) is a long-lasting inflammatory T-cell mediated auto-immune disease. At present, there are various drugs and its pharmaceutical formulations (tablets, capsules, injections and infusions) for its treatment. But, these known formulations suffer with various limitations to reach the site of action - brain. For instance, tablets and capsules undergo significant first-pass effect and fail to reach the actual site of action to shown the intended therapeutic benefit. Even if reached, they show insufficient effect. Similarly, infusions and injections also suffer due to their inability to cross the blood-brain-barrier so as to reach brain. Accordingly, to overcome these limitations, the present disclosure provides a synergistic composition and its intranasal drug delivery formulation of NLCs loaded with active pharmaceutical ingredient, fingolimod and a therapeutic nucleic acid, an antagomir. Accompanying figure is Figure No. 1

No. of Pages : 45 No. of Claims : 8